Business
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound
AXIM® Biotechnologies Completes Pre-Clinical Drug Studies on New Compound Proving Tenfold Greater Inhibition of Tumor Metastasis Than Parent Compound.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis.  “Cancer is a leading cause of death worldwide and distant metastases are the major cause of patient mortality,” said John W. Huemoeller II, Chief Executive Officer of AXIM® Biotech. “Our scientists at Sapphire are aiming to slow down this death rate through their emphasis on metastasis and these positive early findings are nothing but spectacular.” Quiescin Sulfhydryl Oxidase 1 (QSOX1), an enzyme that is over-expressed by tumor cells in numerous cancers, has been shown to be involved in cancer invasion and metastasis. Earlier this year, Sapphire acquired exclusive license rights to a small molecule, SBI-183. SBI-183 has been proven to inhibit the enzymatic activity of QSOX1 and suppress tumor cell invasion in vitro and metastasis of MDA-MB-231 breast tumor cells in vivo. In a non-metastatic xenograft of kidney cancer, SBI-183 suppressed primary kidney tumor growth by 51 percent and in a metastatic xenograft breast cancer model (MDA-MB-231-luc TNBC), SBI-183 reduced lung metastasis by 76 percent compared to control.  A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/87caefd4-4990-4d64-9567-7f9f9883e200 Sapphire scientists have tested over 70 analogs of SBI-183 and discovered that SPX-1009 was tenfold more potent in comparison to SBI-183, in suppressing tumor invasion and metastasis in vitro.  SPX-1009 was first screened in a cell-free enzymatic assay for its ability to inhibit QSOX1 and then tested for its ability to inhibit growth and invasion of triple-negative breast cancer (TNBC) cells (MDA-MB-231), sarcomatoid kidney cancer cells (RCJ-41T2) and pancreatic adenocarcinoma cells (MIAPaCa2). MTT assays were used to measure the effect of the compounds on tumor growth. 2D invasion assays and 3...